XFOR — X4 Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $341.88m
- $354.77m
- $2.56m
Annual income statement for X4 Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3 | 0 | 0 | 0 | 2.56 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 1.76 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63 | 85.1 | 87.6 | 108 | 39 |
| Operating Profit | -60 | -85.1 | -87.6 | -108 | -36.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -62 | -88.7 | -93.8 | -101 | -37.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -62.1 | -88.7 | -93.9 | -101 | -37.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -62.1 | -88.7 | -93.9 | -101 | -37.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -62.1 | -103 | -96.4 | -101 | -37.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -92.7 | -112 | -45.7 | -17.1 | -15.8 |